Leopoldine Lapierre

Toulouse, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study.

Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 05, 2026

Neutropenia Duration During AZA-VEN Induction for AML Is Bimodal and Correlates With Infection Risk.

Neutropenia Duration During AZA-VEN Induction for AML Is Bimodal and Correlates With Infection Risk.

Journal: Blood advances

Published: May 05, 2026

Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide to R-MPV and Ifosfamide to R-AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study.

Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide to R-MPV and Ifosfamide to R-AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study.

Journal: Hematological oncology

Published: February 05, 2026

Characteristics of patients diagnosed for acute myeloid leukemia before and during the 2020 COVID-19 pandemic: the DATAML population-based cohort.

Characteristics of patients diagnosed for acute myeloid leukemia before and during the 2020 COVID-19 pandemic: the DATAML population-based cohort.

Journal: Scientific reports

Published: December 19, 2025

Real-World Evidence Supports Venetoclax as an Additional Option for Patients With t(11;14) Myeloma.

Real-World Evidence Supports Venetoclax as an Additional Option for Patients With t(11;14) Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: March 26, 2025

BCR::ABL1-Positive Acute Myeloid Leukemia.

BCR::ABL1-Positive Acute Myeloid Leukemia.

Journal: American journal of hematology

Published: January 27, 2025

Levofloxacin to Prevent Bacterial Infection in Patients With Acute Myeloid Leukemia Treated by Venetoclax and Azacitidine: A Toulouse-Bordeaux DATAML Registry Study.

Levofloxacin to Prevent Bacterial Infection in Patients With Acute Myeloid Leukemia Treated by Venetoclax and Azacitidine: A Toulouse-Bordeaux DATAML Registry Study.

Journal: Open forum infectious diseases

Published: November 05, 2024

Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature.

Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature.

Journal: Leukemia & lymphoma

Published: August 14, 2024

Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC.

Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC.

Journal: Transplantation and cellular therapy

Published: December 14, 2022

The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials.

The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials.

Journal: Journal of clinical pharmacy and therapeutics

Published: June 14, 2022

"Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies.

"Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies.

Journal: Hematological oncology

Published: March 05, 2022

Nivolumab in refractory cerebral relapse of Hodgkin's lymphoma.

Nivolumab in refractory cerebral relapse of Hodgkin's lymphoma.

Journal: Leukemia & lymphoma

Published: July 13, 2021

Showing 1-12 of 13

Last Updated: 09/26/2026